UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1750) 1750
Newsletter (107) 107
Book Chapter (33) 33
Newspaper Article (14) 14
Transcript (14) 14
Magazine Article (12) 12
Dissertation (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ipilimumab (1700) 1700
science & technology (1359) 1359
life sciences & biomedicine (1337) 1337
humans (1259) 1259
melanoma (897) 897
immunotherapy (862) 862
oncology (829) 829
melanoma - drug therapy (660) 660
male (597) 597
antibodies, monoclonal - therapeutic use (553) 553
antibodies, monoclonal - adverse effects (521) 521
female (496) 496
middle aged (496) 496
cancer (487) 487
metastasis (471) 471
care and treatment (440) 440
aged (409) 409
nivolumab (397) 397
skin neoplasms - drug therapy (338) 338
adult (294) 294
patients (293) 293
melanoma - pathology (289) 289
antineoplastic agents - therapeutic use (278) 278
treatment outcome (271) 271
immunology (268) 268
antineoplastic agents - adverse effects (259) 259
drug therapy (252) 252
research (245) 245
cancer therapies (242) 242
chemotherapy (232) 232
complications and side effects (225) 225
clinical trials (224) 224
pembrolizumab (222) 222
ipilimumab - adverse effects (218) 218
antibodies, monoclonal - administration & dosage (208) 208
ctla-4 antigen - antagonists & inhibitors (206) 206
melanoma - immunology (206) 206
skin neoplasms - pathology (200) 200
immunotherapy - methods (184) 184
tumors (178) 178
antigens (173) 173
antineoplastic agents, immunological - adverse effects (171) 171
antineoplastic combined chemotherapy protocols - therapeutic use (168) 168
immune checkpoint (165) 165
lymphocytes (164) 164
ipilimumab - therapeutic use (163) 163
aged, 80 and over (162) 162
cytotoxicity (159) 159
monoclonal antibodies (158) 158
ctla-4 antigen - immunology (157) 157
programmed cell death 1 receptor - antagonists & inhibitors (156) 156
melanoma - secondary (155) 155
ctla-4 (153) 153
medical research (146) 146
dermatology (144) 144
metastases (144) 144
health aspects (142) 142
medicine & public health (142) 142
neoplasms. tumors. oncology. including cancer and carcinogens (137) 137
melanoma - therapy (135) 135
antineoplastic agents, immunological - therapeutic use (130) 130
neoplasm metastasis (128) 128
analysis (127) 127
lung cancer (127) 127
apoptosis (126) 126
medicine, research & experimental (125) 125
research & experimental medicine (125) 125
t cells (121) 121
toxicity (121) 121
neoplasm staging (120) 120
case report (117) 117
neoplasms - drug therapy (117) 117
animals (116) 116
antineoplastic combined chemotherapy protocols - adverse effects (114) 114
retrospective studies (113) 113
melanoma - mortality (112) 112
immunotherapy - adverse effects (111) 111
ipilimumab - administration & dosage (110) 110
pharmacology & pharmacy (109) 109
development and progression (108) 108
medical prognosis (106) 106
immune system (105) 105
mutation (103) 103
pd-1 (101) 101
prognosis (101) 101
skin cancer (101) 101
antibodies, monoclonal, humanized - adverse effects (100) 100
antibodies, monoclonal, humanized - therapeutic use (100) 100
dosage and administration (100) 100
medicine, experimental (100) 100
abridged index medicus (99) 99
clinical trials as topic (99) 99
usage (99) 99
skin neoplasms - immunology (97) 97
antibodies (93) 93
review (93) 93
lymphocytes t (92) 92
colitis (87) 87
programmed cell death 1 receptor - immunology (87) 87
disease-free survival (84) 84
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1877) 1877
French (23) 23
German (18) 18
Japanese (8) 8
Czech (5) 5
Spanish (5) 5
Danish (4) 4
Russian (3) 3
Chinese (2) 2
Hungarian (2) 2
Norwegian (2) 2
Polish (2) 2
Dutch (1) 1
Hebrew (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 21, pp. 1572 - 1587
..., interleukin-2, ipilimumab, tremelimumab, thalidomide, and lenalidomide. Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Hypothyroidism - chemically induced | Thyroid Function Tests | Hyperthyroidism - diagnosis | Interleukin-2 - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antineoplastic Agents - administration & dosage | Recombinant Proteins - adverse effects | Tetrahydronaphthalenes - adverse effects | Hyperthyroidism - chemically induced | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Diphtheria Toxin - adverse effects | Thyroid Hormones - blood | Anticarcinogenic Agents - adverse effects | Interleukin-2 - analogs & derivatives | Thyroiditis, Autoimmune - chemically induced | Molecular Targeted Therapy - methods | Thyroid Gland - drug effects | Thalidomide - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Hyperthyroidism - blood | Radioimmunotherapy | Hypopituitarism - etiology | Hypothyroidism - diagnosis | Alemtuzumab | Hypothyroidism - etiology | Neoplasms - drug therapy | Iodine Radioisotopes - administration & dosage | Hypopituitarism - complications | Neoplasms - immunology | Hypothyroidism - drug therapy | Quality of Life | Interferon-alpha - adverse effects | Hypothyroidism - blood | Thyroid Gland - metabolism | Antibodies, Neoplasm - adverse effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Complications and side effects | Usage | Thyroid diseases | Diagnosis | Antineoplastic agents | Thyroid gland function tests | Risk factors | Hypothyroidism | Medical diagnosis | Medical treatment | Index Medicus | Review
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 07/2012, Volume 30, Issue 21, pp. 2691 - 2697
.... We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on their management... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article